Myasthenia gravis Exacerbation or Unmasking Associated With Telithromycin Treatment
Neurol 67:2256-2258, Perrot,S.,et al, 2006
Fluoroquinolone Antibiotics Block Neuromuscular Transmission
Neurol 50:804-807, Sieb,J.P., 1998
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Aggravation of Myasthenia Gravis by Erythromycin
J Pediatr 119:155-156, Absher,J.R.&Bale,J.F., 1991
Aggravation of Myasthenia Gravis by Erythromycin
Ann Neurol 28:577-579, May,E.F.&Calvert,P.C., 1990
Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990
Ampicillin May Aggravate Clinical & Experimental Myasthenia Gravis
Arch Neurol 43:255-256, Argov,Z.,et al, 1986
Disorders of Neuromuscular Transmission Caused by Drugs
NEJM 301:409-413, Argov,Z.,et al, 1979
Clinical Syndromes of Myasthenia in Infancy & Childhood
Arch Neurol 35:97, Fenichel,G.M., 1978
Myasthenia Gravis Assoc. with Wasp Sting
JAMA 235:2120, Brumlik,J., 1976
Aggravating Effect of Some Antibiotics on the Neuromuscular Blockage in Myasthenia Gravis
Acta Neurol Scand 40:346, Hokkanes,E., 1964
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
NEJM 392:2309-2320, Nowak,R.J.,et al, 2025
Myasthenia Gravis - Redemption for B-Cell Depletion
NEJM 392:2382-2384, Wolfe,G.I. & Shelly,S., 2025
A Woman with Subacute Progression of Distal Upper Extremity Weakness
Neurol 105:e214212, Zhao,A.J.,et al, 2025
Clinicopathologic Conference, Myasthenia Gravis
NEJM 391:1441-1450, Case 32-2024, 2024
Clinicopathologic Conference, Brain Abscess Due to Infection with Listeria Monocytogeneses
NEJM 391:1529-1538, Case 33-2024, 2024
Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology
Ann Neurol 96:1020-1025, Falso,S.,et al, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022
A New Option is Approved for Patients with Myasthenia Gravis
JAMA 327:417, Voelker, R., 2022
Curtain Sign
NEJM 387:e7, Sherman, S.V., 2022
A 71-Year-Old Man Presenting with Acute Onset Dysarthria and Dysphagia
Neurol 96:180-184, Spagni, G.,et al, 2021
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Thymectomy for Myasthenia Gravis
Neurol 94:705-709, Gronseth, G.S.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Ptosis that Resolves with Application of an Ice Pack
BMJ 369:m1147, Chakraborty, A. & Jacob, J., 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Congenital Myasthenic Syndromes in Adult Neurology Clinic
Neurol 91:e1770-e1777, Kao, J.C.,et al, 2018
Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis
JAMA Neurol 74:60-66, Robeson, K.R.,et al, 2017
A Child with Delayed Motor Milestones and Ptosis
Neurol 88:e158-e163, Ghosh, P.S., 2017
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Myasthenia Gravis Exacerbation after Discontinuing Mycophenolate
Neurol 86:1159-1163, Oskarsson, B.,et al, 2016
Myasthenia Gravis Treated with Autologous Hematopoietic Stem Cell Transplantation
JAMA Neurol 73:652-658,624, Bryant, A.,et al, 2016
A Randomized Controlled Trial of Methotrexate for Patients with Generalized Myasthenia Gravis
Neurol 87:57-64, Pasnoor, M.,et al, 2016
International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Randomized Trial of Thymectomy in Myasthenia Gravis
NEJM 375:511-522,576, Wolfe, G.I.,et al, 2016
Clinical Manifestations of Myasthenia Gravis
UptoDate Aug 2016, Bird, S.J., 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Mechanisms, Causes, and Effects of Hypercapnia
UptoDate Dec, Feller-Kopman, D.J. & Schwartzstein, R.M., 2016
Myasthenia Gravis after Botulinum Toxin Type A Injection
Turk J Neurol 22:143-144, Tekce, H.D.,et al, 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Myasthenia in Pregnancy: Best Practice Guidelines from a UK Multispecialty Working Group
JNNP 85:538-543, Norwood, F.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014